Is the business good?
How good a business is CRNX?
Crinetics Pharmaceuticals, Inc. keeps −1303% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−1303%
Operating margin · Biotechnology median −72% · 12 months to Q2 2026
- Share count, year on year
- +13%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 891%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −105568% |
| FY2021 | −9991% |
| FY2022 | −3544% |
| FY2023 | −5547% |
| FY2024 | −32613% |
| FY2025 | −6715% |
Details›
- Operating margin12 months to Q2 2026
- −1303%
- Net margin12 months to Q2 2026
- −1190%
- Free cash flow margin
- −1009%
- R&D as % of revenue
- 891%
- Revenue, trailing twelve months
- $42M
- Free cash flow, trailing twelve months
- −$425M
- Net income, trailing twelve months
- −$502M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.